Stocktoria
Enlivex Ltd. ENLV
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-07-30
Enlivex Ltd. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $9.2M | $10.6M | $19.0M | $18.7M | $12.9M | $6.1M | $5.6M | $4.0M | $1.7M | $2.0M |
| Operating income | -$15.0M | -$15.9M | -$29.4M | -$25.8M | -$19.3M | -$9.8M | -$8.6M | -$5.3M | -$2.2M | -$2.8M |
| Income tax | $382.6M | — | — | — | — | — | — | — | $28,000 | $216,000 |
| Net income | $1.2B | -$15.0M | -$29.1M | -$31.1M | -$14.5M | -$11.8M | -$9.4M | -$4.2M | -$2.5M | -$2.9M |
| EPS (diluted) | $25.48 | $-0.73 | $-1.56 | $-1.69 | $-0.81 | $-0.90 | — | — | — | — |
| Operating cash flow | -$10.4M | -$13.0M | -$23.5M | -$24.0M | -$17.5M | -$11.0M | -$7.0M | -$3.2M | -$2.3M | -$15.5M |
| Free cash flow | -$10.5M | -$13.1M | -$23.8M | -$32.1M | -$19.2M | -$12.0M | -$7.2M | -$3.6M | -$2.4M | -$15.7M |
| Cash & equivalents | $1.9M | $3.3M | $813,000 | $49.9M | $11.2M | $5.7M | $3.9M | $9.7M | $9.0M | $3.0M |
| Total assets | $2.3B | $27.7M | $36.8M | $67.6M | $95.1M | $40.4M | $17.6M | $11.0M | $9.5M | $10.6M |
| Total liabilities | $392.1M | $4.1M | $6.7M | $10.8M | $10.1M | $4.9M | $6.3M | $1.3M | $1.0M | — |
| Shareholders' equity | $1.9B | $23.6M | $30.1M | $56.8M | $85.0M | $35.5M | $11.3M | $9.7M | $8.5M | $2.8M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.